SG11201408153YA - Prostate-specific membrane antigen antibody drug conjugates - Google Patents

Prostate-specific membrane antigen antibody drug conjugates

Info

Publication number
SG11201408153YA
SG11201408153YA SG11201408153YA SG11201408153YA SG11201408153YA SG 11201408153Y A SG11201408153Y A SG 11201408153YA SG 11201408153Y A SG11201408153Y A SG 11201408153YA SG 11201408153Y A SG11201408153Y A SG 11201408153YA SG 11201408153Y A SG11201408153Y A SG 11201408153YA
Authority
SG
Singapore
Prior art keywords
international
drug conjugates
antibody drug
san diego
amino acid
Prior art date
Application number
SG11201408153YA
Inventor
Richard S Barnett
Feng Tian
Anna-Maria A Hays Putnam
Marco Gymnopoulos
Nick Knudsen
Andrew Beck
Ying Sun
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of SG11201408153YA publication Critical patent/SG11201408153YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 December 2013 (12.12.2013) WIPOIPCT (10) International Publication Number WO 2013/185117 A1 (51) International Patent Classification: A61K 47/48 ( 2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/044850 7 June 2013 (07.06.2013) English English (30) Priority Data: 61/656,883 7 June 2012 (07.06.2012) (71) Applicant: AMBRX, INC. [US/US]; 10975 North Torrey Pines Road, Suite 100, La Jolla, CA 92037 (US). (72) Inventors: BARNETT, Richard S.; 306 Belmont Court, San Marcos, CA 92069 (US). TIAN, Feng; 8374 Orange Haven Place, San Diego, CA 92129 (US). PUTNAM, An- na-maria A. Hays; 11522 Cesped Drive, San Diego, CA 92124 (US). GYMNOPOULOS, Marco; 3620 3rd Aven­ ue, San Diego, CA 92103 (DE). KNUDSEN, Nick; 1916 Rohn Road, Escondido, CA 92025 (US). BECK, Andrew; 4732 Kansas Street, Apt. 2, San Diego, CA 92116 (US). SUN, Ying; 14972 Avenida Venusto #65, San Diego, CA 92128 (US). (74) Agent: WALLEN, John W., Ill; 10975 North Torrey Pines Road, Suite 100, La Jolla, CA 92037 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Ug (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) l> i-H oo i-H cn i-H o CJ o & (54) Title: PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES (57) Abstract: This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates com­ prising at least one non-naturally-encoded amino acid. Disclosed herein are aPSMA antibodies with one or more non-naturally en­ coded amino acids and further disclosed are antibody drug conjugates wherein the aPSMA antibodies of the invention are conjug - ated one to or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-trans- lationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dol­ astatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for us­ ing such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin ana­ logs, including therapeutic, diagnostic, and other biotechnology uses.
SG11201408153YA 2012-06-07 2013-06-07 Prostate-specific membrane antigen antibody drug conjugates SG11201408153YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656883P 2012-06-07 2012-06-07
PCT/US2013/044850 WO2013185117A1 (en) 2012-06-07 2013-06-07 Prostate-specific membrane antigen antibody drug conjugates

Publications (1)

Publication Number Publication Date
SG11201408153YA true SG11201408153YA (en) 2015-01-29

Family

ID=48699944

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201408153YA SG11201408153YA (en) 2012-06-07 2013-06-07 Prostate-specific membrane antigen antibody drug conjugates
SG10201702176XA SG10201702176XA (en) 2012-06-07 2013-06-07 Prostate-specific membrane antigen antibody drug conjugates

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201702176XA SG10201702176XA (en) 2012-06-07 2013-06-07 Prostate-specific membrane antigen antibody drug conjugates

Country Status (14)

Country Link
US (2) US10800856B2 (en)
EP (2) EP3536700A1 (en)
JP (1) JP6425650B2 (en)
KR (1) KR102143664B1 (en)
CN (3) CN108727466B (en)
AU (2) AU2013270686B2 (en)
CA (1) CA2874854C (en)
DK (1) DK2858676T3 (en)
ES (1) ES2725329T3 (en)
IL (3) IL235895B (en)
MX (3) MX363116B (en)
NZ (2) NZ703298A (en)
SG (2) SG11201408153YA (en)
WO (1) WO2013185117A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
PL2605789T3 (en) 2010-08-17 2019-11-29 Ambrx Inc Modified relaxin polypeptides and their uses
CN104662000B (en) 2012-05-15 2018-08-17 索伦托医疗有限公司 Drug conjugates and its coupling method and purposes
WO2013192360A1 (en) 2012-06-19 2013-12-27 Ambrx, Inc. Anti-cd70 antibody drug conjugates
PL2968440T3 (en) 2013-03-15 2019-12-31 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
FR3005051A1 (en) * 2013-04-25 2014-10-31 Pf Medicament DERIVATIVES OF DOLASTATIN 10 AND AURISTATINES
WO2015057876A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
US10675355B2 (en) 2013-12-27 2020-06-09 Var2 Pharmaceuticals Aps VAR2CSA-drug conjugates
EP3086815B1 (en) 2013-12-27 2022-02-09 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
CN106470708B (en) 2014-04-25 2019-12-31 皮埃尔法布雷医药公司 Antibody-drug-conjugates and their use for the treatment of cancer
JP6258523B2 (en) 2014-04-25 2018-01-10 ピエール、ファーブル、メディカマン IGF-1R antibody-drug conjugate and its use for the treatment of cancer
RS62860B1 (en) 2014-09-17 2022-02-28 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
EP3226909A1 (en) 2014-12-03 2017-10-11 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
US10590165B2 (en) 2015-01-28 2020-03-17 Sorrento Therapeutics, Inc. Antibody drug conjugates
RU2708461C2 (en) * 2015-02-15 2019-12-09 Цзянсу Хэнжуй Медсин Ко., Лтд. Ligand conjugate with cytotoxic drug preparation, method and application thereof
WO2017031034A2 (en) * 2015-08-14 2017-02-23 Rc Biotechnologies, Inc. Covalent linkers in antibody-drug conjugates and methods of making and using the same
JP6412906B2 (en) 2015-11-03 2018-10-24 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Compound, linker-drug and ligand-drug complex
AU2017225982B2 (en) 2016-03-02 2023-10-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
US20210308277A1 (en) * 2016-11-14 2021-10-07 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers
MX2019008449A (en) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof.
WO2018223108A1 (en) 2017-06-02 2018-12-06 Ambrx, Inc. Methods and compositions for promoting non-natural amino acid-containing protein production
WO2019191728A1 (en) * 2018-03-29 2019-10-03 Ambrx, Inc. Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates
CN109232712B (en) * 2018-08-21 2021-08-03 联宁（苏州）生物制药有限公司 Preparation method of intermediate for antibody drug conjugate
CN111328333B (en) * 2019-09-29 2023-10-03 烟台迈百瑞国际生物医药股份有限公司 Method for preparing antibody drug conjugate intermediate by acid method and application thereof
EP3828196A4 (en) * 2019-09-29 2022-04-27 MabPlex International Co., Ltd. Method for preparing antibody-drug conjugate intermediate by means of acid method and application thereof
WO2024077277A1 (en) 2022-10-07 2024-04-11 Ambrx, Inc. Drug linkers and antibody conjugates thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US971A (en) 1838-10-08 Mode of pbeventing dust from rising from threshing-machines when in
US7850A (en) 1850-12-24 Improvement in the manufacture of starch from maize
FR2504010B1 (en) 1981-04-15 1985-10-25 Sanofi Sa ANTI-CANCER MEDICINAL PRODUCTS CONTAINING THE RICIN-ASSOCIATED CHAIN ASSOCIATED WITH ANTIMELANOMA ANTIBODY AND PROCESS FOR THEIR PREPARATION
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
DE3680924D1 (en) 1985-01-14 1991-09-26 Neorx Corp METAL RADIONUCLIDE MARKED PROTEIN FOR DIAGNOSIS AND THERAPY.
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6150508A (en) 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
WO1999045026A1 (en) 1998-03-05 1999-09-10 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2444098C (en) 2001-04-19 2016-06-21 The Scripps Research Institute Methods and composition for the production of orthogonal trna-aminoacyltrna synthetase pairs
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
EP2277542B1 (en) 2001-06-01 2014-04-16 Cornell Research Foundation Inc. Modified antibodies to prostrate-specific membrane antigen and uses thereof
AU2002305767B2 (en) 2001-09-20 2008-04-10 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for PSMA
AU2002356844C1 (en) 2001-10-23 2010-03-04 Amgen Fremont Inc. PSMA antibodies and protein multimers
MXPA05006836A (en) 2002-12-22 2005-08-16 Scripps Research Inst Protein arrays.
US7910693B2 (en) 2004-04-19 2011-03-22 Proscan Rx Pharma Inc. Prostate cancer diagnosis and treatment
NZ550934A (en) * 2004-05-19 2010-05-28 Medarex Inc Chemical linkers and conjugates thereof
WO2006050262A2 (en) 2004-11-01 2006-05-11 The Regents Of The University Of California Compositions and methods for modification of biomolecules
CN101341118A (en) * 2004-12-22 2009-01-07 Ambrx公司 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CA3005835C (en) * 2004-12-22 2023-01-31 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP1851251A2 (en) 2005-02-18 2007-11-07 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
US8067006B2 (en) * 2005-04-06 2011-11-29 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
US7976852B2 (en) * 2005-04-26 2011-07-12 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
DK1912677T3 (en) * 2005-06-20 2014-01-13 Psma Dev Company L L C PSMA antibody-drug conjugates
US8871720B2 (en) * 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
AU2007333737A1 (en) * 2006-12-18 2008-06-26 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
DK2326350T3 (en) * 2008-09-08 2013-12-16 Psma Dev Company L L C RELATIONS TO KILL PSMA EXPRESSING TAXAN RESISTANT CANCER CELLS
WO2010036964A2 (en) * 2008-09-26 2010-04-01 Ambrx Inc. Modified animal erythropoietin polypeptides and their uses
DK3170821T3 (en) * 2011-05-27 2021-10-11 Ambrx Inc COMPOSITIONS CONTAINING, INVOLVING PROCEDURES, AND USES OF NON-NATURAL AMINO ACID-BINDED DOLASTATIN DERIVATIVES
KR102356286B1 (en) * 2011-05-27 2022-02-08 암브룩스, 인코포레이티드 Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
WO2013068874A1 (en) * 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates

Also Published As

Publication number Publication date
CA2874854A1 (en) 2013-12-12
CN104619349B (en) 2018-07-10
SG10201702176XA (en) 2017-04-27
EP3536700A1 (en) 2019-09-11
CN104619349A (en) 2015-05-13
IL235895A0 (en) 2015-01-29
AU2013270686A1 (en) 2015-01-22
NZ703298A (en) 2016-04-29
US20220033518A1 (en) 2022-02-03
US20150152190A1 (en) 2015-06-04
KR102143664B1 (en) 2020-08-11
AU2013270686B2 (en) 2016-11-10
AU2017200877B2 (en) 2018-08-30
CN108727466B (en) 2023-04-28
IL258937B (en) 2019-08-29
KR20150023563A (en) 2015-03-05
AU2017200877A1 (en) 2017-03-02
MX2014015029A (en) 2015-03-03
NZ713941A (en) 2017-02-24
MX2023010485A (en) 2023-09-18
JP2015521590A (en) 2015-07-30
IL268538A (en) 2019-09-26
CN116514899A (en) 2023-08-01
CA2874854C (en) 2023-03-14
ES2725329T3 (en) 2019-09-23
JP6425650B2 (en) 2018-11-21
EP2858676A1 (en) 2015-04-15
DK2858676T3 (en) 2019-05-13
WO2013185117A1 (en) 2013-12-12
IL268538B (en) 2020-11-30
EP2858676B1 (en) 2019-03-13
MX2019002732A (en) 2023-02-23
MX363116B (en) 2019-03-11
CN108727466A (en) 2018-11-02
IL235895B (en) 2018-05-31
IL258937A (en) 2018-06-28
US10800856B2 (en) 2020-10-13

Similar Documents

Publication Publication Date Title
SG11201408153YA (en) Prostate-specific membrane antigen antibody drug conjugates
SG11201408347UA (en) Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201900201YA (en) Methods for quantitating individual antibodies from a mixture
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201811432WA (en) Rna for cancer therapy
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201808693WA (en) Anti-il-33 antibodies, compositions, methods and uses thereof
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201807188VA (en) Modified cells for immunotherapy
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201807912SA (en) Vaccine against rsv
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201806419RA (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201906392WA (en) Nucleoside-modified rna for inducing an immune response against zika virus
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof